NASDAQ:CRMD CorMedix Q3 2026 Earnings Date & Estimates $7.48 +0.09 (+1.23%) As of 01:45 PM Eastern This is a fair market value price provided by Massive. Learn more. CorMedix is estimated to report Q3 2026 earnings on Wednesday, November 11, 2026, before market opens. The conference call is scheduled for 8:30 AM ET. Research:ProfileEarnings HistoryForecast Upcoming Earnings Announcement QuarterQ3 2026Announcement DateNovember 11, 2026TimeBefore Market OpensConference Call8:30 AM ET Add to CalendarGoogle Calendar (opens in a new tab)Outlook (opens in a new tab)Yahoo Calendar (opens in a new tab) What Analysts Expect from CorMedix in Q3 2026CorMedix is expected to post earnings of -$0.1050 per share on revenue of $53.23 million. In the same quarter a year earlier CorMedix reported $1.26 per share on revenue of $104.28 million. CorMedix last reported on August 13, 2026, posting $0.29 per share and beating the $0.2380 consensus estimate. CorMedix has beaten the consensus EPS estimate in 7 of its last 8 quarters.Consensus EstimatesConsensus EPS-$0.1050Expected Revenue$53.23 millionPrior-Year EPS$1.26Prior-Year Revenue$104.28 millionExpected EPS Growth-108.3%Expected Revenue Growth-49.0%Recent Track RecordLast ReportedQ2 2026Last Quarter EPS$0.29 (Beat by +$0.0520)Last Quarter Revenue$101.93 millionEPS Beat Rate7 of last 8 quartersPrepare for the Q3 2026 CallEarnings HistoryCompany ProfileQ2 2026 Earnings ReportQ1 2026 Earnings ReportQ4 2025 Earnings Report CorMedix Q3 2026 Earnings FAQ When does CorMedix report Q3 2026 earnings? CorMedix (NASDAQ:CRMD) is estimated to report Q3 2026 earnings on Wednesday, November 11, 2026, before market opens. This date is estimated from past reporting schedules and may change once the company confirms it. What time is CorMedix's Q3 2026 earnings call? CorMedix's Q3 2026 earnings conference call is scheduled for Wednesday, November 11, 2026 at 8:30 AM ET. MarketBeat streams the conference call audio and posts the transcript as soon as possible on the earnings announcement date. What is the consensus EPS estimate for CorMedix? Analysts expect CorMedix to post earnings of -$0.1050 per share for Q3 2026. How much revenue is CorMedix expected to report? The consensus revenue estimate for CorMedix is $53.23 million for Q3 2026. CorMedix Earnings HeadlinesReviewing CorMedix (NASDAQ:CRMD) and Eyepoint Pharmaceuticals (NASDAQ:EYPT)October 4, 2026 | americanbankingnews.comCorMedix Inc (NASDAQ:CRMD) Stock Has Consensus Target Price of $15.00October 3, 2026 | americanbankingnews.comRent out your stocks?If you owned a rental house, you would collect rent while you waited for it to rise in value. A covered call lets you do something similar with stocks you already own. Own at least 100 shares and you can get paid cash today for agreeing to sell them at a higher price later. That cash is yours to keep no matter what happens next. Bill Poulos breaks it down in The Retirement Paycheck Playbook, normally $29.97, free today.October 14 at 1:00 AM | Profits Run (Ad)Oppenheimer initiates coverage of CorMedix at outperformSeptember 23, 2026 | msn.comOppenheimer avvia la copertura di CorMedix con rating outperformSeptember 23, 2026 | it.investing.comCorMedix出席富国银行第21届年度医疗健康大会：增长与风险并存September 10, 2026 | cn.investing.comSee More CorMedix Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like CorMedix? Sign up for Earnings360's daily newsletter to receive timely earnings updates on CorMedix and other key companies, straight to your email. Email Address About CorMedixCorMedix (NASDAQ:CRMD). is a biopharmaceutical company focused on developing and commercializing products designed to prevent and treat infectious and inflammatory diseases. The company’s lead product is DefenCath® (taurolidine and heparin), an antimicrobial catheter-lock solution intended to reduce the risk of catheter-related bloodstream infections in adult patients with kidney failure who receive chronic hemodialysis through a central venous catheter. The U.S. Food and Drug Administration approved DefenCath in 2023. The product is used to fill and lock the lumens of dialysis catheters between treatment sessions, helping protect against infection while maintaining catheter patency. CorMedix markets DefenCath in the United States and is focused on expanding its use within the U.S. dialysis-care market. CorMedix was founded in 2006 and is headquartered in Berkeley Heights, New Jersey. The company continues to evaluate additional applications for its taurolidine-based technology and related opportunities in infection prevention and other high-risk healthcare settings. David Mehalick serves as CorMedix’s president and chief executive officer.View CorMedix ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Citi Stock Falls Despite Earnings Beat: What Investors Need to KnowDon’t Get NVIDIA’s Reflection AI Interest Wrong: Its Moat Could DeepenPBF Energy's Stunning Rally Faces a Critical TestA Chinese Rival Just Spooked Memory Stocks—How Worried Should Micron Investors Be?Albertsons Is Betting on a Turnaround—But Will It Pay Off?PepsiCo's Earnings Beat Masks a Bigger Problem With Its North American BusinessTax Credit Turmoil: Why Enphase and SolarEdge Face a Tough Road Upcoming Earnings Interactive Brokers Group (10/15/2026)Marsh & McLennan Companies (10/15/2026)The PNC Financial Services Group (10/15/2026)Charles Schwab (10/15/2026)U.S. Bancorp (10/15/2026)Prologis (10/15/2026)Taiwan Semiconductor Manufacturing (10/15/2026)Truist Financial (10/16/2026)Travelers Companies (10/16/2026)HDFC Bank (10/17/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
